kshivets o. esophageal and cardioesophageal cancer surgery

20
Oleg Kshivets, MD, PhD Siauliai Public Hospital, Siauliai, Lithuania

Upload: oleg-kshivets

Post on 21-Apr-2017

1.779 views

Category:

Health & Medicine


2 download

TRANSCRIPT

Page 1: Kshivets O. Esophageal and Cardioesophageal Cancer Surgery

Oleg Kshivets, MD, PhD Siauliai Public Hospital, Siauliai, Lithuania

Page 2: Kshivets O. Esophageal and Cardioesophageal Cancer Surgery

5-YEAR SURVIVAL OF ESOPHAGEAL/CARDIOESOPHAGEAL CANCER PATIENTS AFTER RADICAL SURGERY SIGNIFICANTLY DEPENDED ON PHASE TRANSITION “EARLY-INVASIVE CANCER”, LYMPH NODE METASTASES AND CELL RATIO FACTORS

Oleg Kshivets Surgery Department, Siauliai Public Hospital, Lithuania   OBJECTIVE: We examined factors associated with low/high-risk of generalization of

esophageal/cardioesophageal cancer (ECEC) (T1-4N0M1A) after complete (R0) esophagogastrectomies (EG).    METHODS: We analyzed data of 407 consecutive ECEC patients (ECECP) (age=55.6±8.6 years; tumor size=6.7±3.3 cm) radically operated and monitored in 1975-2010 (m=305, f=102;EG Garlock=271, EG Lewis=136, combined EG with resection of pancreas, liver, diaphragm, colon transversum, lung, trachea, pericardium, splenectomy=125; adenocarcinoma=212, squamous=185, mix=10; T1=62, T2=96, T3=140, T4=109; N0=167, N1=56, M1A=184, G1=116, G2=96, G3=195; early ECEC=43, invasive=364). Multivariate Cox modeling, clustering, SEPATH, Monte Carlo, bootstrap and neural networks computing were used to determine any significant dependence.    RESULTS: Overall life span (LS) was 1612.6±2070.5 days and cumulative 5-year survival (5YS) reached 40%, 10 years – 32.7%, 20 years – 23.5%. 101ECECP lived more than 5 years without ECEC. 215ECECP died because of ECEC. Cox modeling displayed (Chi2=46.0, df=5, P=0.000) that 5YS of ECECP significantly depended on: phase transition (PT) early-invasive ECEC in terms of synergetics, PT N0--N1-M1A, cell ratio factors (CRF) (ratio between cancer cells – CC and blood cells subpopulations) (P=0.001-0.029). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive ECEC (rank=1), PT N0--N1-M1A (rank=2), healthy cells/CC, monocytes/CC, segmented neutrophils/CC, eosinophils/CC, stab neutrophils/CC, leucocytes/CC, lymphocytes/CC, thrombocytes/CC, erythrocytes/CC. Correct prediction of 5YS was 100% by neural networks computing.

    CONCLUSIONS:5YS of ECECP after radical procedures significantly depended on: 1) PT “early-invasive ECEC”; 2) PT N0--N1-M1A; 3) CRF.

Page 3: Kshivets O. Esophageal and Cardioesophageal Cancer Surgery

Males……………………………………………………………305

Females………….…………………………………………….102

Age=55.6±8.6 years Tumor Size=6.7±3.3 cm Esophagogastrectomies Ivor-

Lewis……………......136 Esophagogastrectomies Garlock………………..

…..271 Combined procedures with resection of

pancreas, liver, diaphragm, VCS, colon transversum, lung, trachea, pericardium, splenectomy …………….….125

Page 4: Kshivets O. Esophageal and Cardioesophageal Cancer Surgery

T1……..62 N0..…..167 G1..………116 T2……..96 N1……...56 G2…..……..96 T3……140 M1A….184 G3.….……195 T4……109 Early Cancer……………………………………….…….43 Invasive Cancer.............................................364 Adenocarcinoma…………………………………….212 Squamous Cell Carcinoma……..……………….185 Mix Carcinoma..…………………….......................10

Page 5: Kshivets O. Esophageal and Cardioesophageal Cancer Surgery

5-Year Survivors…………..………….101 (24.8%)

Losses……………………………………215 (52.8%)

General Life Span=1612.6±2070.5 days For 5-Year Survivors=4404.4±2543.9 days For Losses=649.8±388.2 days

Cumulative 5-Year Survival……………....40.0%

Cumulative 10-Year Survival…..............32.7%

Page 6: Kshivets O. Esophageal and Cardioesophageal Cancer Surgery

Survival FunctionGeneral Esophageal and Cardioesophageal Cancer Patients Survival after

Complete Esophagogastrectomies, n=407Cumulative 5-Year Survival=40%; 10-Year survival=32.7%

Complete Censored

-5 0 5 10 15 20 25 30 35 40

Years after Esophagogastrectomies

0.0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

0.9

1.0

1.1

1.2

Cum

ulat

ive

Prop

ortio

n Su

rviv

ing

Page 7: Kshivets O. Esophageal and Cardioesophageal Cancer Surgery

Cumulative Proportion Surviving (Kaplan-Meier)Cumulative 5-Year Survival of Early Cancer Patients=100%

Cumulative 5-Year Survival of Invasive Cancer Patients=33.2%P=0.000 by Log-Rank Test

Complete Censored

0 5 10 15 20 25 30 35 40

Years after Esophagogastrectomies

-0.2

0.0

0.2

0.4

0.6

0.8

1.0

Cum

ulat

ive

Prop

ortio

n Su

rviv

ing

Invasive Cancer Patients=364 Early Cancer Patients=43

Page 8: Kshivets O. Esophageal and Cardioesophageal Cancer Surgery

Cumulative Proportion Surviving (Kaplan-Meier)Cumulative 5-Year Survival of Cancer Patients with N0=60.3%

Cumulative 5-Year Survival of Cancer Patients with N1-M1A=25.1%P=0.000 by Log-Rank Test

Complete Censored

0 5 10 15 20 25 30 35 40

Years after Esophagogastrectomies

0.0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

0.9

1.0

Cum

ulat

ive

Prop

ortio

n Su

rviv

ing

Cancer Patients with N0=167 Cancer Patients with N1-M1A=240

Page 9: Kshivets O. Esophageal and Cardioesophageal Cancer Surgery

Factors Wald df P

Phase Transition Early-Invasive LC 5.864 1 0.015 Phase Transition N0—N1-2 11.871 1

0.001 Leucocytes/Cancer Cells 5.844 1 0.016 Segmented Neutrophils/Cancer Cells 4.794 1 0.029 Monocytes/Cancer Cells 4.998 1 0.025

Page 10: Kshivets O. Esophageal and Cardioesophageal Cancer Surgery

Discriminant Function Analysis Summary Wilks' Lambda: 0.703 approx. F (8,307)=16.179 p< 0.0000; Correct Classification Rate=78.5% Wilks'-Lambda P Phase Transition Early-Invasive Lung Cancer 0.714 0.029 Phase Transition N0—N1-2 0.744 0.000 Erythrocytes/Cancer Cells 0.718 0.012 Leucocytes/Cancer Cells 0.719 0.010 Segmented Neutrophils/Cancer Cells 0.719 0.010 Lymphocytes/Cancer Cells 0.716 0.018 Monocytes/Cancer Cells 0.714 0.029 Healthy Cells/Cancer Cells 0.720 0.008

Page 11: Kshivets O. Esophageal and Cardioesophageal Cancer Surgery

5-Year Survivors LossesBaseline Errors=0.000 Total 215 101Area under ROC Curve=1.0 Correct 215

101Correct Classification Rate=100% Wrong 0 0

Page 12: Kshivets O. Esophageal and Cardioesophageal Cancer Surgery

Factor Rank Sensitivity Phase Transition Early-Invasive Cancer 1 49239

Phase Transition N0---N12 2 15916 Healthy Cells/Cancer Cells 3 6775 Monocytes/Cancer Cells 4 5656 Segmented Neutrophils/Cancer Cells 5 4612 Eosinophils/Cancer Cells 6 4176 Stab Neutrophils/Cancer Cells 7 3601 Leucocytes/Cancer Cells 8 3469 Lymphocyte/Cancer Cells 9 3136 Thrombocytes/Cancer Cells 10 2925 Erythrocytes/Cancer Cells 11 2885

Page 13: Kshivets O. Esophageal and Cardioesophageal Cancer Surgery

Factor Useful for 5-Year Survival

Phase Transition Early-Invasive Cancer Yes

Phase Transition N0---N1M1A Yes Leucocyte/Cancer Cells Yes Monocyte/Cancer Cells Yes Healthy Cells/Cancer Cells Yes

Page 14: Kshivets O. Esophageal and Cardioesophageal Cancer Surgery
Page 15: Kshivets O. Esophageal and Cardioesophageal Cancer Surgery

Number of Samples=3333 Significant Factors Rank Kend.Tau-A P Healthy Cells/Cancer Cells 1 0.230 0.000 Erythrocytes/Cancer Cells 2 0.226 0.000 Leucocytes/Cancer Cells 3 0.215 0.000 Lymphocytes/Cancer Cells 4 0.205 0.000 Thrombocytes/Cancer Cells 5 0.202 0.000 Segmented Neutrophils/Cancer Cells 6 0.190 0.000 Eosinophils/Cancer Cells 7 0.175 0.000 Phase Transition N0—N1M1A 8 -0.1720.000 Monocytes/Cancer Cells 9 0.158 0.000 Phase Transition Early-Invasive Cancer 10 -0.1250.001 Stab Neutrophils/Cancer Cells 11 0.083 0.048

Page 16: Kshivets O. Esophageal and Cardioesophageal Cancer Surgery

3 4 5 6 7 8

Glucose02.557.510Lymphocytes/Cancer Cells

00

0.10.1

0.20.2

0.30.3

0.40.4

0.50.5

0.60.6

0.70.7

0.80.8

0.90.9

11

5-Ye

ar S

urviv

al

5-Ye

ar S

urviv

al

P=0.000z=a+bx+cx (̂1.5)+dx 2̂+ex (̂2.5)+fx 3̂+gy (̂0.5)lny+hy (̂0.5)+ie (̂-y)

r 2̂=0.22525238 DF Adj r 2̂=0.20246569 FitStdErr=0.41643509 Fstat=11.157259a=-324.15986 b=995.38663 c=-1201.3125 d=607.59325 e=-144.67162

f=13.358387 g=-1.246218 h=5.1686977 i=3.3595194

3 4 5 6 7 8

Glucose00.511.522.5Monocytes/Cancer Cells

00

0.10.1

0.20.2

0.30.3

0.40.4

0.50.5

0.60.6

0.70.7

0.80.8

0.90.9

11

5-Ye

ar S

urviv

al

5-Ye

ar S

urviv

al

P=0.000z=a+blnx+c(lnx) 2̂+d(lnx) 3̂+e(lnx) 4̂+f(lnx) 5̂+glny+h(lny) 2̂+i(lny) 3̂+j(lny) 4̂+k(lny) 5̂

r 2̂=0.16790831 DF Adj r 2̂=0.13779973 FitStdErr=0.4329842 Fstat=6.1546145a=-384.21482 b=1274.4403 c=-1669.3899 d=1080.7312 e=-345.52251 f=43.62225

g=0.5669461 h=-0.099389185 i=-0.2903548 j=-0.10570297 k=-0.011258385

Page 17: Kshivets O. Esophageal and Cardioesophageal Cancer Surgery
Page 18: Kshivets O. Esophageal and Cardioesophageal Cancer Surgery
Page 19: Kshivets O. Esophageal and Cardioesophageal Cancer Surgery

5-year survival and life span of esophageal and cardioesophageal cancer patients after complete esophagogastrectomies significantly depended on:

1) phase transition early—invasive cancer; 2) phase tranzition N0---N1M1A; 3) cell ratio factors: ratio of cancer cell

population to blood cell subpopulations in integral patient organism.

Page 20: Kshivets O. Esophageal and Cardioesophageal Cancer Surgery